Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity.

Abstract: Substituted dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and which are useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and which are useful as medicaments for the treatment of, inter alia, COPD.

Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity.

Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase and useful as medicaments for the treatment of, inter alia, COPD.

Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Abstract: A compound of formula 1 wherein: A is a group selected from X? is an anion with a single negative charge; R1 and R2 are each independently a C1-C4-alkyl optionally substituted with hydroxy or halogen; and R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen, with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.

Abstract: The present invention relates to new anticholinergics of general formula 1 wherein A, X?, and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions.

Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a betamimetic 2, or a solvate or hydrate thereof, optionally in the form of the enantiomers, mixtures of the enantiomers, or in the form of the racemates thereof, processes for preparing them and their use in the treatment of respiratory complaints.

Abstract: Xanthenecarboxylates of formula 1 wherein: A is a group selected from X? is an anion with a single negative charge; R is hydroxy, methyl, hydroxymethyl, ethyl, —CF3, —CHF2, or fluorine; R1 and R2, which are identical or different, are each C1-C5-alkyl which is optionally substituted by C3-C6-cycloalkyl, hydroxy, or halogen, or R1 and R2 together denote a —C3-C5-alkylene-bridge; and R3, R4, R3?, and R4?, which are identical or different, are each hydrogen, —C1-C4-alkyl, —C4-alkyloxy, hydroxy, —CF3, —CHF2, —CN, —NO2, or halogen, or a physiologically acceptable salt thereof, processes for preparing, them and their use in pharmaceutical compositions.

Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 ?wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Abstract: The present invention relates to cyanothiophenes of general formula wherein the Rs are defined as in the claims, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly a glugacon receptor-antagonistic activity.